Elevated serum free light chains predict cardiovascular events in type 2 diabetes

Srikanth Bellary*, Jeffrey M. Faint, Lakhvir K. Assi, Colin A. Hutchison, Stephen J. Harding, Neil T. Raymond, Anthony H. Barnett

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8%) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95% CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. © 2014 by the American Diabetes Association.

Original languageEnglish
Pages (from-to)2028-2030
Number of pages3
JournalDiabetes Care
Volume37
Issue number7
Early online date17 Apr 2014
DOIs
Publication statusPublished - 31 Jul 2014

Fingerprint

Type 2 Diabetes Mellitus
Cardiovascular Diseases
Light
Serum
Immunoglobulin Light Chains
Biochemistry
C-Reactive Protein
Albumins
Creatinine
Cohort Studies
Research Design
Logistic Models
Odds Ratio
Mortality
Therapeutics

Bibliographical note

© 2014 by the American Diabetes Association.

Cite this

Bellary, S., Faint, J. M., Assi, L. K., Hutchison, C. A., Harding, S. J., Raymond, N. T., & Barnett, A. H. (2014). Elevated serum free light chains predict cardiovascular events in type 2 diabetes. Diabetes Care, 37(7), 2028-2030. https://doi.org/10.2337/dc13-2227
Bellary, Srikanth ; Faint, Jeffrey M. ; Assi, Lakhvir K. ; Hutchison, Colin A. ; Harding, Stephen J. ; Raymond, Neil T. ; Barnett, Anthony H. / Elevated serum free light chains predict cardiovascular events in type 2 diabetes. In: Diabetes Care. 2014 ; Vol. 37, No. 7. pp. 2028-2030.
@article{dda49fb176a0449fbe3376eb9b06b025,
title = "Elevated serum free light chains predict cardiovascular events in type 2 diabetes",
abstract = "OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8{\%}) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95{\%} CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. {\circledC} 2014 by the American Diabetes Association.",
author = "Srikanth Bellary and Faint, {Jeffrey M.} and Assi, {Lakhvir K.} and Hutchison, {Colin A.} and Harding, {Stephen J.} and Raymond, {Neil T.} and Barnett, {Anthony H.}",
note = "{\circledC} 2014 by the American Diabetes Association.",
year = "2014",
month = "7",
day = "31",
doi = "10.2337/dc13-2227",
language = "English",
volume = "37",
pages = "2028--2030",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association Inc.",
number = "7",

}

Bellary, S, Faint, JM, Assi, LK, Hutchison, CA, Harding, SJ, Raymond, NT & Barnett, AH 2014, 'Elevated serum free light chains predict cardiovascular events in type 2 diabetes', Diabetes Care, vol. 37, no. 7, pp. 2028-2030. https://doi.org/10.2337/dc13-2227

Elevated serum free light chains predict cardiovascular events in type 2 diabetes. / Bellary, Srikanth; Faint, Jeffrey M.; Assi, Lakhvir K.; Hutchison, Colin A.; Harding, Stephen J.; Raymond, Neil T.; Barnett, Anthony H.

In: Diabetes Care, Vol. 37, No. 7, 31.07.2014, p. 2028-2030.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Elevated serum free light chains predict cardiovascular events in type 2 diabetes

AU - Bellary, Srikanth

AU - Faint, Jeffrey M.

AU - Assi, Lakhvir K.

AU - Hutchison, Colin A.

AU - Harding, Stephen J.

AU - Raymond, Neil T.

AU - Barnett, Anthony H.

N1 - © 2014 by the American Diabetes Association.

PY - 2014/7/31

Y1 - 2014/7/31

N2 - OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8%) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95% CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. © 2014 by the American Diabetes Association.

AB - OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8%) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95% CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. © 2014 by the American Diabetes Association.

UR - http://www.scopus.com/inward/record.url?scp=84903526436&partnerID=8YFLogxK

U2 - 10.2337/dc13-2227

DO - 10.2337/dc13-2227

M3 - Article

C2 - 24742658

VL - 37

SP - 2028

EP - 2030

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 7

ER -

Bellary S, Faint JM, Assi LK, Hutchison CA, Harding SJ, Raymond NT et al. Elevated serum free light chains predict cardiovascular events in type 2 diabetes. Diabetes Care. 2014 Jul 31;37(7):2028-2030. https://doi.org/10.2337/dc13-2227